In this issue of Blood, Ngo et al 1 identify selective injury to sinusoidal endothelial cells caused by venetoclax and azacitidine, revealing a therapyassociated mechanism that links bone marrow (BM) niche damage to impaired hematopoietic recovery.
Sun et al. (Thu,) studied this question.